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Background: The opposing renin-angiotensin system (RAS) and kallikrein-kinin system (KKS) are upregulated in
pregnancy and localize in the utero-placental unit. To test their participation as counter-regulators, circulating
angiotensin II (AII) was exogenously elevated and the bradykinin B2 receptor (B2R) was antagonized in pregnant
guinea-pigs. We hypothesized that disrupting the RAS/KKS balance during the period of maximal trophoblast
invasion and placental development would provoke increased blood pressure, defective trophoblast invasion
and a preeclampsia-like syndrome.
Methods: Pregnant guinea-pigs received subcutaneous infusions of AII (200 μg/kg/day), the B2R antagonist
Bradyzide (BDZ; 62.5 microg/kg/day), or both (AII + BDZ) from gestational day 20 to 34. Non-pregnant cycling
animals were included in a control group (C NP) or received AII + BDZ (AII + BDZ NP) during 14 days. Systolic blood
pressure was determined during cycle in C NP, and on the last day of infusion, and 6 and 26 days thereafter in the
remaining groups. Twenty six days after the infusions blood and urine were extracted, fetuses, placentas and
kidneys were weighed, and trophoblast invasion of spiral arteries was defined in the utero-placental units by
immunocytochemistry.
Results: Systolic blood pressure transiently rose in a subgroup of the pregnant females while receiving AII +
BDZ infusion, but not in AII + BDZ NP. Plasma creatinine was higher in AII- and BDZ-treated dams, but no
proteinuria or hyperuricemia were observed. Kidney weight increased in AII + BDZ-treated pregnant and
non-pregnant females. Aborted and dead fetuses were increased in dams that received AII and AII + BDZ. The
fetal/placental weight ratio was reduced in litters of AII + BDZ-treated mothers. All groups that received
interventions during pregnancy showed reduced replacement of endothelial cells by extravillous trophoblasts
in lateral and myometrial spiral arteries.
Conclusions: The acute effects on fetal viability, and the persistently impaired renal/placental sufficiency and
incomplete arterial remodeling implicate the RAS and KKS in the adaptations in pregnancy. The results partially
confirm our hypothesis, as a preeclampsia-like syndrome was not induced. We demonstrate the feasibility of
characterizing systemic and local modifications in pregnant guinea-pig, supporting its use to study normal
placentation and related disorders.
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The renin-angiotensin system (RAS) has traditionally been
considered the main vasopressor stimulus. This was be-
cause angiotensin II (AII), which was considered the ter-
minal peptide of the RAS, exerts a potent effect when
binding to its AT1 receptor (AT1R). However, the func-
tional scope of the RAS and the number of its participants
have now been extended [1] by non-proteolytic RAS acti-
vation through the renin/prorenin receptor [2], a vasodi-
lating receptor of AII (AT2R) and several intermediate
vasodilatory peptides/receptors, including angiotensin-(1–
7)/Mas, angiotensin-(3–8) or AIV/AT4R, and angiotensin-
(1–9)/AT2R [3-7].
The kallikrein-kinin system (KKS) includes both a plasma
and a tissue cascade. Plasma kallikrein is synthesized in the
liver, released into circulation, and activated by coagulation
factor XII to liberate bradykinin and lys-bradykinin from
high-molecular-weight kininogen. The main tissue kalli-
krein, KLK1, is synthetized in various organs and releases
lys-bradykinin by cleaving low-molecular-weight kininogen.
Kinins activate the main constitutive B2 receptor (B2R) and
the B1 receptor, the latter of which is scarcely expressed in
normal tissues and is mainly induced by tissue injury, endo-
toxins, or cytokines [8]. The tissue KKS has a vasodepressor
role, which has been unmasked by converting enzyme in-
hibitors [9-11] and blockers of its main vasodilatory consti-
tutive receptor, the bradykinin B2R [12].
The enzymatic cascades of the RAS and the KKS are vir-
tually mirror images of each other. Bradykinin and angio-
tensin II enhance angiogenesis while angiotensinogen is
antiangiogenic [13], and the angiotensin II/AT1R and
bradykinin/B2R pathways are proinflammatory. However,
both peptidergic systems have antagonic vasomotor and
pleiotropic effects, impacting vascular smooth muscle, fibro-
sis, cardiovascular hypertrophy, platelet aggregation, oxida-
tive stress and electrolyte balance. The two systems are
ubiquitous and have endocrine, paracrine, and autocrine
roles [14,15]. Moreover, they maintain active cross-talk at
various sites, from activation of prorenin by kallikrein
[16,17] to heterodimerization of their main receptors AT1R
and B2R [18-21]. Overall, their vasodilating peptides inte-
grate a rich network of potentiating pathways [22].
During gestation, the RAS and the KKS are associated
with up- or down-regulation of maternal blood pressure,
and with auto/paracrine effects at the feto-maternal inter-
face [19,23-26]. Moreover, in vitro, the invasive capacity of
immortalized trophoblasts is impaired by angiotensin II
[27] and enhanced by bradykinin B2R-mediated stimulation
[28]. Thus, we believe that the RAS and KKS are interre-
lated antagonistic systems that should be jointly studied.
The guinea-pig is an attractive model for such studies, as
it shares with humans an extensive vascular transformation
[29], a hemomonochorial placenta, the temporal pattern of
progesterone levels [30], a preeclamptic-like syndromeassociated with reduced placental perfusion [31], a utero-
placental repertoire of vasoactive and angiogenic factors in
functionally equivalent structures [22,32-35] which includes
the B1 and B2 [36] as well as the AT1 and AT2 bradykinin
and angiotensin receptors respectively (Acuña and Valdés,
unpublished observation).
Here we tested our hypothesis that disturbing the en-
dogenous balance between the RAS and the KKS in preg-
nant guinea-pigs, during the period of maximal trophoblast
invasion and placental development [37], by the administra-
tion of angiotensin II or Bradyzide – a potent non-peptide
antagonist of the B2R [38] - would provoke a defective
trophoblast invasion, fetal losses, blood pressure changes and
preeclampsia-like morphological and functional alterations.
Methods
Animals
All experiments were conducted according to the Guide
for the Care and Use of Laboratory Animals (National
Research Council, USA), and were approved by the In-
stitutional Review Board for Ethics and Animal Welfare,
and by the Ethics Committee of FONDECYT (Fondo
Nacional de Desarrollo Científico y Tecnológico, Chile).
Virgin Pirbright white guinea-pigs of ~600 g were kept
under controlled conditions of humidity and temperature
(25°C), with a 12-h light–dark cycle. Females were exam-
ined daily for perforation of the vaginal closure membrane.
Upon this occurrence, they were caged with fertile males,
and the following day was defined as day 1. Between days
18–20, pregnancy was confirmed by ecography (Aloka
Flexus SSD-1100; Hitachi Aloka Medical, Tokyo, Japan).
On day 20, pregnant guinea-pigs were anesthetized with in-
traperitoneal ketamine (60 mg/kg) and xylazine (4 mg/kg)
prior to subcutaneous implantation of Alzet 2ML2 osmotic
pumps (Durect, Cupertino, CA) in the interscapular region.
Over 14 days, these pumps delivered either saline solu-
tion (control; n = 6), angiotensin II (Sigma) 200 μg/kg/day
(AII; n = 7), Bradyzide (Sigma) 62.5 μg/kg/day (BDZ; n = 5),
or angiotensin II plus Bradyzide (AII + BDZ; n = 6). The
dose of AII was subpressor, as determined in a pilot study
in non-pregnant guinea-pigs. To evaluate the direct and the
persistent consequences of the interventions, systolic blood
pressure was determined during the last hours of the in-
fusion on gestational day 34, and at 6 and 26 days after
withdrawal of the osmotic pumps. Blood pressure was
measured under anesthesia in the pad of the right paw
compressed by a neonatal blood pressure cuff (Critikon,
General Electric Healthcare, Connecticut, EEUU) using a
Power Lab 8 SP system (ADInstruments, Sidney, Australia).
Blood pressure data were analyzed with the Labchart
graphic software 6.1 Pro (ADInstruments). After the
blood pressure measurement on gestational day 34, the
osmotic pumps were extracted while the animals were
still anesthetized.
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cycling guinea-pigs. The first group included control
non-pregnant females (C NP; n = 5); in them the sys-
tolic blood pressure was measured in random days of
the estrous cycle. The second group received subcuta-
neous infusions of AII + BDZ for 14 days (AII + BDZ
NP; n = 6), and systolic blood pressure was measured
on the last day of infusion, and at 6 and 26 days after
its discontinuation.
On gestational day 60 or 26 days after AII + BDZ infu-
sion in non-pregnant females, with the animals under
ketamine and xylazine, urine was withdrawn from the
bladder for determination of protein (Bradford method)
and creatinine (Beckman Autoanalyser, Fullerton, CA) and
blood from the left ventricle for creatinine and uric acid
determination (Beckman Autoanalyser). Then the animals
were euthanized with an overdose of ketamine/xylazine,
and the uterus, feto-placental units, and kidneys were re-
moved. The fetuses, placentas, and kidneys were weighed
after trimming off the umbilical cord, amniotic membranes,
and perirenal fat. Fetal loss was attributed to demise if an
atrophic or necrotic feto-placental unit was observed, or
to abortion when a fetus observed by ultrasonography was
absent at term, since miscarriages in guinea-pigs are fre-
quently not accompanied by persistence of the implant-
ation site (Elger, personal communication). Only units
with a live fetus were included for measurements of fetal
and placental weight and for immunohistochemical stud-
ies. A central cross-section through the placenta, subpla-
centa, implantation site, and underlying myometrium was
fixed as a single block. The placenta, and the subplacental
decidua and myometrium were also isolated in other feto-
placental units; from these, the fetal/placental weight ratio
was calculated as a marker of placental efficiency [39]. Tis-
sues were immediately fixed with phosphate-buffered 10%
formalin for 24 h, then dehydrated in a graded series of
ethanol and xylene dilutions, and embedded in Paraplast-
Plus® (Sigma, St. Louis, MO). Sections (6 μm) were mounted
on silanized slides.
Immunostaining procedure
Immunostaining was performed at room temperature.
Deparaffinized sections were rehydrated using ethanol,
rinsed three times for five minutes each in phosphate-
buffered saline with 50 mM Tris–HCl, and submitted
to heat-induced antigen retrieval using citrate buffer
(pH 6.0). Endogenous peroxidases were blocked by in-
cubation in 10% H2O2 for ten minutes. Sections were then
incubated in a humid chamber for 30 min with protein
block (Cas-Block®; Zymed, San Francisco, CA), followed
by incubation for 18 h at 4°C with anti-pancytokeratin
mouse monoclonal antibody (1:50, P2871, Sigma). Sec-
tions were immunostained using a biotin-streptavidin-
peroxidase system (LSAB + ®, DakoCytomation). Finally,the samples were treated for 15 min with 0.1% (w/v) 3-3′-
diaminobenzidine in buffer containing 0.05% H2O2. The
slides were counterstained with Harris hematoxylin (Sigma).Evaluation of uterine arterial trophoblast invasion
Spiral arteries were identified as lateral if localized in the
periphery of the subplacenta, or myometrial if in the uter-
ine smooth muscle below the placental bed. The extravil-
lous trophoblast (EVT) was defined as intramural when
located in the media of the spiral artery, and as endovascu-
lar when lining the lumen of the spiral artery and replacing
endothelial cells. Photographic images were acquired with a
Nikon CoolPix 4500 camera (Nikon Inc., Tokyo, Japan),
coupled to a Zeiss AxioImager AX.10 microscope (Carl
Zeiss, CA). The portion of the endovascular trophoblast
replacing endothelial cells was calculated by measuring
the arterial perimeter occupied by cytokeratin-positive
cells, using Axiovision 4.8.2.0 LE (Carl Zeiss AG, Inc.,
Oberkochen, Germany). Groups were compared accord-
ing to the percentage of intraluminal perimeter occupied
by cytokeratin-positive cells in the lateral and myometrial
spiral arteries.Statistics
A Bayesian analysis [40] was performed to test differences
between systolic blood pressures in different groups and
periods and the proportion between viable versus lost fe-
tuses according to treatment. Systolic pressure was mod-
eled as a multivariate normal distribution with different
mean vectors and variance-covariance matrices for groups
and periods. Data are expressed as mean and dot-plot of
individual values. The logarithm of the non-viable fetuses/
[1 – the predicted non-viable fetuses] was modeled as a
normal distribution, with group-dependent median and
variances. After proving that variances were similar among
groups, a common variance was used. For each group, we
calculated the proportion of viable fetuses, the differences
between these proportions, and their credible intervals
(CI). Data are expressed as proportion of live fetuses and
CI. The analyses were performed with the open-source
OpenBUGS program. Differences were considered signifi-
cant when the CI did not cross zero.
A one-way ANOVA with Fisher’s LSD post-hoc test was
performed to determine the effects of the interventions on
fetal, placenta, and kidney weights. Student’s t-test was
used to evaluate differences in the protein/creatinine index
among the different groups of pregnant dams and the
non-pregnant females that received AII + BDZ. Data are
expressed as mean and dot-plot of individual values. Data
were analyzed using Graphpad Prism 6.01 (GraphPad Inc.,
San Diego, CA) and were considered significantly different
when P < 0.05.
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Maternal blood pressure
Pregnant dams in gestational day 34, which were on
the fourteenth day of AII + BDZ infusion, exhibited a
dual effect; in them a group displayed a marked in-
crease of systolic blood pressure while another main-
tained values within that of control animals and those
receiving single infusions (Figure 1A). This elevation
subsided after infusion cessation, such that the systolic
blood pressure at gestational day 40 (not shown) and
60 were similar to those in the control and singly
treated groups (Figure 1B). The blood pressure eleva-
tion induced by AII + BDZ in a subgroup of pregnant
animals did not occur in AII + BDZ-treated non-
pregnant females. (Figure 1A).A
B
Figure 1 Systolic blood pressure in pregnant and non-pregnant
guinea-pigs treated with angiotensin II (AII), bradyzide (BDZ),
or AII + BDZ. Systolic blood pressure on gestational days 34 (A) and
60 (B) in controls (C), AII, BDZ and AII + BDZ treated dams and in AII +
BDZ-treated non-pregnant females (AII + BDZ NP). The broken line
depicts the mean systolic blood pressure of 73.2 ± 7.5 SEM mm Hg in
untreated non-pregnant females (C NP); continuous line represents
mean values.Fetal, placental, and maternal outcomes
The proportions of viable versus lost fetuses (including
abortions and fetal demises) were reduced in the groups
treated with AII (0.75; CI, 0.57–0.89) and with AII + BDZ
(0.68; CI, 0.50–0.84) compared to the control group (0.95;
CI, 0.8–0.99, P < 0.05); the ratio of viable/lost fetuses did
not differ between the control and BDZ-treated groups
(0.80; CI, 0.57–0.95). Infusions with BDZ and AII + BDZ
were associated with reduced fetal weight, compared to
animals infused with only AII (P < 0.01) (Figure 2A). The
fetal/placental weight ratio was also reduced in litters of
mothers treated with AII + BDZ, compared to those of
controls (P < 0.05) and the AII group (P < 0.01) (Figure 2B).
The placental weights of the treated dams were not differ-
ent from those of controls.
Kidney weights were similar in all groups. AII-treated
dams had higher plasma creatinine levels than controls
(0.46 ± 0.05 versus 0.33 ± 0.02 mg/dl; P < 0.01). Both preg-
nant and non-pregnant animals receiving AII + BDZ pre-
sented reduced plasma creatinine levels compared with





Figure 2 Fetal weight and fetal/placental weight ratios from
dams treated with saline, angiotensin II (AII), Bradyzide (BDZ),
or AII + BDZ. (A) Fetal weight. (B) Fetal/placental weight ratio.
Continuous line represents mean values. *P < 0.05; †P < 0.01.
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0.04 mg/dl for AII and BDZ; P < 0.05). Neither control,
treated dams or non-pregnant AII + BDZ treated females
exhibited proteinuria or hyperuricemia.
Remodeling of uterine arteries
In the lateral spiral arteries no intramural trophoblasts were
observed; all treated groups exhibited decreased intralum-
inal replacement of endothelium by extravillous tropho-
blasts (P < 0.005 for the AII-, AII + BDZ- and P < 0.0005 for
the BDZ-treated groups versus control) (Figure 3A). In
myometrial spiral arteries, the perimeter occupied by endo-
luminal EVT was reduced in the groups receiving AII,
BDZ, (P < 0.0005 for both) and AII + BDZ (P < 0.005) as
compared to controls. (Figure 3B). In summary, both the
isolated and combined interventions resulted in reductions
of endoluminal EVT in lateral and myometrial spiral arteries








Figure 3 Intraluminal extravillous trophoblasts in spiral arteries on
gestational day 60 in dams treated with saline, angiotensin II (AII),
Bradyzide (BDZ), or AII + BDZ. (A) Lateral spiral artery endothelium
replaced by extravillous trophoblasts (EVT) (% perimeter) in dams
treated with saline, AII, BDZ, or AII + BDZ. (B) Myometrial spiral artery
endothelium replaced by EVT (% perimeter) in dams treated with
saline, AII, BDZ, or AII + BDZ. Continuous line represents mean values.
**P < 0.005; ***P < 0.0005.Discussion
The results of the present study indicate that a transient
disruption of the balance between the RAS and the KKS
in favor of the RAS in midpregnancy alters the maternal
adaptation to pregnancy.
At the level of the utero-placental unit, tilting the RAS/
KKS balance towards vasoconstriction caused fetal losses
and placental insufficiency, and reduced the replacement of
endothelium by endovascular trophoblasts in the spiral ar-
teries. Infusions were delivered between gestational days 20
and 34, which is when extravillous trophoblasts display the
maximal decidual penetration [37]; thus the secondary fetal
losses may be attributed to decreased decidual vasodilata-
tion, hyperpermeability, and priming of the spiral arteries
[41]. The retardation of trophoblast invasion, reflected at
term by a reduction of endovascular trophoblasts in viable
feto-placental units, was likely due to B2R blockade and
excessive AT1R stimulation as observed in HTR-8/SVneo
cells [27,28]. Guinea-pigs express AT1 and AT2 receptors
in the placenta, decidua, and extravillous trophoblasts
(Acuña and Valdés, unpublished observation), similar to
what has been described in humans [26,32,42-45]. However,
the deleterious effects of AT1R antagonists in pregnancy
[46,47] preclude their use for identifying the main receptor
stimulated by excess angiotensin.
The acute effect of angiotensin II plus a B2R blocker
provoked an increase of systolic blood pressure in a subset
of the group (responders) to values that were not attained
with single interventions and in non-pregnant females re-
ceiving the combined treatment. The responders are prob-
ably bradykinin-dependent when circulating angiotensin II
surpasses the endogenous gestational levels.
This study leaves unresolved questions regarding why
additive effects of combined interventions were observed
for some, but not all, study parameters. The discordance
between the lack of additive effect on fetal weight and the
summatory impact on the fetal/placental weight ratio could
be because the combined intervention induces greater fetal
losses, which favor the growth of the remaining units. The
higher plasma creatinine in dams that received BDZ—ab-
sent in the AII + BDZ group—could be attributed to a lack
of the protective effect of B2R in the face of gestational
hyperfiltration [48], as reported in B2R-null mice [49].
In the AII + BDZ group, this could be compensated by
positive regulation of BdkrB2 gene expression by AII,
and by AT1R-mediated activation of B2R expression
[50]. These postulates exemplify how, in vivo, an intricate
vasodilatory/pleiotropic network and tissue-specific effects
could diminish the effects of angiotensin II stimulation
and B2R blockade.
The presently observed persistent changes in tropho-
blast invasion partially confirm our hypothesis that dis-
turbing the endogenous balance between the RAS and
the KKS in mid-pregnancy would provoke a defective
Figure 4 Representative sections of spiral arteries on day 60 of gestation in dams treated with saline (C), Bradyzide (BDZ), angiotensin
II (AII) angiotensin II + Bradyzide (AII + BDZ). Endoluminal trophoblasts in lateral and myometrial spiral arteries are depicted in the upper and
lower panel, respectively. The whole-mount haematoxylin/eosin section of the guinea-pig utero-placental interface includes in blue ovals the
zones from which the microphotographs were acquired; trophoblasts were identified by anti-cytokeratin and highlighted by * and interrupted
lines. Magnification x400 in upper panel and x100 in lower panel.
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type was not reproduced. It remains to be tested whether
dams would develop this syndrome if the interventions
were continued to term. In humans, a maintained increase
in circulating AII could correlate with the agonistic auto-
antibody to AT1R [23], the T235 polymorphism of the
angiotensinogen gene [51], and the redox conformation ofangiotensinogen that facilitates angiotensin release [24].
Decreased stimulation of the B2R by bradykinin could
derive from a depressed KKS, as observed in women who
present with pregnancy hypertension or preeclampsia
[52,53]. Lastly, the AII + BDZ combination might resemble
the heterodimerization of the AT1R and B2R, which sensi-
tizes the AT1R and blunts the response of the B2R [19]. A
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balance would be magnified along its course by the recruit-
ment of intermediate effectors.
Conclusions
By transiently tilting the balance of the opposing RAS and
KKS systems during the period of maximal trophoblast in-
vasion, we demonstrated deleterious effects of AII and B2R
blockade in pregnant guinea-pigs. Further understanding of
the effects of the opposing RAS and KKS could inspire the
development of pharmacological interventions to enhance
the KKS in order to counteract excessive preponderance of
AT1R activation in maternal circulation and the utero-
placental interface in preeclampsia, mediated by angioten-
sin II and the agonistic AT1R autoantibody. This study also
demonstrates the feasibility of characterizing systemic and
local modifications in the pregnant guinea-pig, supporting
the use of this model in studies of normal placentation and
related disorders.
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